Peptide basics
An empty registry can mean 1990, not nothing
On this page
ClinicalTrials.gov opened in 2000, and mandatory registration for most applicable trials arrived later still.
Anything approved before then can hold a valid approval and have no registry entry at all.
Sermorelin is the clearest case here: approved in 1990 as GEREF, with zero registered trials.
So its empty registry reflects when it was developed, not an absence of testing — and that exception does not extend to compounds that were never approved.
This page explains why some approved compounds have no registry record and how to tell that situation apart from a genuine absence of evidence. No dose, schedule or route appears.
When registration became compulsory
ClinicalTrials.gov began operating in 2000. The requirement that most applicable trials be registered before enrolment, with results reported afterwards, came with the FDA Amendments Act of 2007 and the Final Rule that followed.13
Trials conducted before that were not required to appear anywhere public. A drug developed in the 1980s could go through its entire programme and leave no trace in the registry.1
Sermorelin is the case on this site
Sermorelin holds an FDA approval for GEREF dating from 1990. Its registered trial count is zero. Both facts are correct, and together they look contradictory only if you assume the registry covers all of history.2
It is the only compound tracked here in that position. Every other compound with an empty registry also has no approval, which is a completely different situation.2
How the exception gets misused
The argument runs: plenty of well-established drugs have no registry entry, so an empty registry means nothing. The first clause is true and the conclusion does not follow.1
The exception applies to compounds that went through approval before registration existed. It does not apply to a compound with no approval, no marketing authorisation anywhere, and no trials — for which the empty registry means exactly what it appears to mean.12
Why this site names the exception in the list
Our page listing compounds with no registered trial names sermorelin alongside 25 unapproved research chemicals. Leaving it unannotated in that company would invite precisely the wrong inference, so the caveat travels with the list rather than sitting in a footnote.2
Common questions
Were the original sermorelin trials published?
Work from that era exists in the literature. What does not exist is a registry record, which is a different and more structured kind of document.
Do old approvals get reviewed again?
Approvals can be revisited, and safety monitoring continues for marketed products. An old approval is not automatically re-examined against modern evidence standards.
Does this apply to compounds approved outside the US?
Other countries have their own registries with their own start dates. The same logic applies: check whether an approval exists before treating an empty registry as explained.
Sources
- RegulatoryFDAAA 801 and the Final Rule — registration requirements and datesU.S. National Library of Medicine, 2025clinicaltrials.gov/policy/fdaaa-801-final-rule ↗↩ Back to text
- RegulatoryDrugs@FDA — sermorelin (GEREF) approval recordU.S. Food and Drug Administration, 2026www.accessdata.fda.gov/scripts/cder/daf/ ↗↩ Back to text
- RegulatoryClinicalTrials.gov — history and background of the registryU.S. National Library of Medicine, 2026clinicaltrials.gov/about-site/about-ctg ↗↩ Back to text